TELA BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.375 USD | -1.69% |
|
-15.34% | -34.14% |
| Apr. 15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
| Mar. 22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
Financials (USD)
| Sales 2024 * | 74.93M | Sales 2025 * | 94.14M | Capitalization | 110M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M | Net income 2025 * | -34M | EV / Sales 2024 * | 1.46 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
-2.44
x | P/E ratio 2025 * |
-3.41
x | Employees | 227 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on TELA Bio, Inc.
More recommendations
More press releases
| 1 day | -0.45% | ||
| 1 week | -13.93% | ||
| Current month | -21.52% | ||
| 1 month | -22.34% | ||
| 3 months | -36.88% | ||
| 6 months | -25.96% | ||
| Current year | -32.78% |
1 week
4.34
5.19
1 month
4.345.78
Current year
4.347.84
1 year
4.2311.26
3 years
4.2316.53
5 years
4.2323.55
10 years
4.2323.55
| Managers | Title | Age | Since |
|---|---|---|---|
Antony Koblish
FOU | Founder | 58 | 12-04-16 |
Roberto Cuca
DFI | Director of Finance/CFO | 57 | 21-09-26 |
Marissa Conrad
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lisa Colleran
BRD | Director/Board Member | 66 | 20-04-19 |
Douglas Evans
CHM | Chairman | 59 | 20-04-19 |
Antony Koblish
FOU | Founder | 58 | 12-04-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4.36 | -2.02% | 37 298 |
| 24-04-24 | 4.45 | -0.45% | 85,296 |
| 24-04-23 | 4.47 | -2.19% | 127,300 |
| 24-04-22 | 4.57 | -3.79% | 165,029 |
| 24-04-19 | 4.75 | -7.77% | 119,515 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.45
USD
Average target price
14.6
USD
Spread / Average Target
+228.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.78% | 110M | |
| -2.89% | 185B | |
| -2.43% | 107B | |
| -4.10% | 67.55B | |
| +11.10% | 54.6B | |
| +15.86% | 47.42B | |
| +3.86% | 42.24B | |
| +9.55% | 28.24B | |
| +1.85% | 26.42B | |
| +12.40% | 25.66B |
- Stock Market
- Equities
- TELA Stock
